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Introduction: Crohn’s disease (CD) is a disabling chronic enteropathy sustained by a harmful T-cell response
toward antigens of the gut microbiota in genetically susceptible subjects. Growing evidence highlights the safety
and possible efficacy of mesenchymal stem cells (MSCs) as a new therapeutic tool for this condition. Therefore, we
aimed to investigate the effects of bone marrow-derived MSCs on pathogenic T cells with a view to clinical application.
Methods: T-cell lines from both inflamed and non-inflamed colonic mucosal specimens of CD patients and from
healthy mucosa of control subjects were grown with the antigen muramyl-dipeptide in the absence or presence of
donors’ MSCs. The MSC effects were evaluated in terms of T-cell viability, apoptotic rate, proliferative response,
immunophenotype, and cytokine profile. The role of the indoleamine 2,3-dioxygenase (IDO) was established by adding
a specific inhibitor, the 1-methyl-DL-tryptophan, and by using MSCs transfected with the small interfering RNA (siRNA)
targeting IDO. The relevance of cell-cell contact was evaluated by applying transwell membranes.
Results: A significant reduction in both cell viability and proliferative response to muramyl-dipeptide, with
simultaneous increase in the apoptotic rate, was found in T cells from both inflamed and non-inflamed CD mucosa
when co-cultured with MSCs and was reverted by inhibiting IDO activity and expression. A reduction of the activated
CD4+CD25+ subset and increase of the CD3+CD69+ population were also observed when T-cell lines from CD mucosa
were co-cultured with MSCs. In parallel, an inhibitory effect was evident on the expression of the pro-inflammatory
cytokines tumor necrosis factor-α, interferon-γ, interleukin-17A and -21, whereas that of the transforming growth factor-β
and interleukin-6 were increased, and production of the tolerogenic molecule soluble HLA-G was high. These latter
effects were almost completely eliminated by blocking the IDO, whose activity was upregulated in MSCs co-cultured
with CD T cells. The use of a semipermeable membrane partially inhibited the MSC immunosuppressive effects. Finally,
hardly any effects of MSCs were observed when T cells obtained from control subjects were used.
Conclusion: MSCs exert potent immunomodulant effects on antigen-specific T cells in CD through a complex paracrine
and cell-cell contact-mediated action, which may be exploited for widespread therapeutic use.* Correspondence: rachele.ciccocioppo@unipv.it; peter.kruzliak@savba.sk
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Crohn’s disease (CD) is a disabling, chronic inflammatory
bowel disease triggered and sustained by a dysregulated
immune response toward antigens of the gut microbiota
in genetically susceptible individuals [1]. Thanks to the re-
cent strides made in understanding the fine mechanisms
responsible for tissue injury, a number of new molecules
have been developed and successfully tested in experimen-
tal colitis models for therapeutic purposes [2]. However,
when used in clinical trials, most of them resulted in dis-
appointing outcomes [3], probably because they were
endowed with a single target although the inflammatory
response is complex and redundant [2]. This has led to
the need for alternative strategies, and cellular therapies,
based mainly on the use of stem cells, represent an area of
increasing interest thanks to their multi-target action [4].
Among them, mesenchymal stem cells (MSCs) seem to be
the best candidate for clinical application by virtue of their
easy isolation and ex vivo expansion, their ability to mi-
grate to sites of inflammation where they display potent
regenerative function, and their lack of significant im-
munogenicity, thus allowing them to be infused without
the need for preventive immunoablation [5]. Moreover,
MSCs have potent immune-regulatory action by virtue of
direct cell-cell contact and production of soluble factors,
making them particularly attractive for the treatment of
immune-mediated diseases [6]. In this regard, the most
studied action is that on T cells, where they inhibit both
alloantigen- and mitogen-induced proliferation [7], sup-
press the generation of cytotoxic T lymphocytes [8], and
favour the expansion of the regulatory subsets: CD4
+CD25+ transcription factor forkhead box factor (FoxP3)+
and interleukin (IL)-10-producing cells [9, 10]. However,
there is still much debate on the mechanisms and mole-
cules involved in the immunological action of MSCs [11]
because most of the in vitro studies have been carried out
by co-culturing MSCs with peripheral blood T cells from
healthy subjects [7–10] rather than with T cells isolated
from damaged organs of affected patients. Indeed, in re-
cent years, MSCs have been shown to display different
behaviour in terms of dampening inflammation and
expanding regulatory T-cell populations, depending on
the specific disease setting [12]. Consequently, MSCs
are not expected to have similar effects in different
chronic inflammatory conditions. This prompted us to
investigate the mechanisms of immunomodulation of
MSCs in CD [13], where no definitive results were ob-
tained when MSCs were applied to treat the luminal
[14–16] or fistulising [17–19] forms of CD, although
this strategy seems promising and safe [14–20]. The aim
of our study, therefore, was to investigate the effects of
MSCs on mucosal T-cell lines (TCLs) specific for the
muramyl dipeptide (MDP), a motif common to peptidogli-
can of the bacterial cell wall against which the abnormalimmune response is mounted [21], which represents the




Twelve patients who had CD (F/M: 8/4, median age of
46.5 years, range of 27–78 years) and who were under-
going both laboratory tests and lower endoscopy as
standard workup for their disease [22] were recruited in
order to obtain both peripheral blood mononuclear cells
(PBMCs) and lamina propria mononuclear cells (LPMCs).
Further biological samples were collected from four
CD patients (F/M: 1/3, median age of 47 years, range
of 28–62) who underwent surgical stricturoplasty or
resection for stenosis or both. In all cases, the diagnosis
of CD was established according to the widely accepted
criteria [22], and the patients’ clinical features are shown
in Table 1. Twelve control subjects (F/M: 8/4, median
age of 41 years, range of 18–52 years) undergoing per-
ipheral blood harvest and colonoscopy were also en-
rolled in the study; irritable bowel syndrome was
diagnosed in each case, and no patient was taking any
medication. The approval by the Fondazione IRCCS
Policlinico San Matteo Bio-Ethics Committee was ob-
tained (protocol number 20130002683, administrative
procedure number 20130012860, approved on 6 June
2013), and each patient and control gave written in-
formed consent.
Mesenchymal stem cell preparation
Fifty millilitres of bone marrow blood had been har-
vested from five healthy donors (F/M: 2/3, median age
of 35 years, range of 18–61) in order to obtain MSCs for
therapeutic purposes [23], and the residual aliquots were
used for the present experiments. Briefly, after 48-h
culture of bone marrow blood, non-adherent cells were
removed and medium was replaced twice a week. Ad-
herent cells were propagated until passage 3, when they
were characterized and cryopreserved until use. MSC
identification criteria were as follows: spindle-shape
morphology, viability of more than 90 %, immunopheno-
type showing the expression of CD73, CD90, and CD105
surface molecules (>95 %) and the absence of CD34,
CD45, and CD31 markers (<5 %), differentiation ability
toward adipogenic and osteogenic lineages, and genetic
stability. In addition, because the immunomodulatory
secretory profile may change among MSC populations
obtained from different donors, we used enzyme-linked
immunosorbent assay (ELISA) tests to evaluate either
the cytokine profile or the human leukocyte antigen
(HLA)-G production of each MSC population used and
analysed the polymorphisms of the HLA-G exon 8 in
the 3′ untranslated region that contains a 14-base pair
Table 1 Patients’ clinical features at enrollment
Patient code Age/Sex Disease duration, years Disease localization CDAI Therapy
#1 58 years/M 5 Ileo-colonic 170 MESA
#2 27 years/F 2 Ileal 293 MESA, AZA
#3 49 years/F 11 Colonic 253 MESA, AZA
#4 33 years/F 0 Colonic 255 AB, MESA
#5 78 years/M 33 Ileo-colonic 198 MESA
#6 48 years/F 0 Ileo-colonic 274 AB, MESA, PRED
#7 28 years/F 13 Ileo-colonic 426 MESA, BIO
#8 56 years/M 0 Colonic 313 BIO
#9 36 years/F 0,5 Colonic 288 MESA, AZA, PRED
#10 45 years/F 1 Ileo-colonic 301 MESA, AB
#11 49 years/M 0 Colonic 350 BIO-AZA
#12 28 years/F 10 Ileo-colonic 80 MESA
#13 32 years/M 7 Ileo-colonic 320 PRED - MESA
#14 62 years/F 17 Ileo-colonic 274 BIO, AZA
#15 47 years/M 11 Ileo-colonic 216 AZA, AB
#16 28 years/M 3 Ileo-colonic 368 BIO, AZA
CDAI Crohn’s disease activity index, M male, MESA mesalamine, F female, AZA azathioprine, AB antibiotics, PRED prednisone, BIO biologic (Infliximab)
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Hviid et al. [24]. In this regard, indeed, it has been re-
ported that the insertion of 14-base pair sequence is as-
sociated with instability of HLA-G mRNA and lower
levels of soluble HLA-G in the serum of healthy individ-
uals [25]. Furthermore, pregnant women homozygous
for HLA-G 14-base pair insertion have a significantly
lower plasma level of soluble HLA-G than those hetero-
zygous (insertion/deletion) for or lacking (deletion/dele-
tion) the HLA-G 14 base pair [26]. In regard to our
MSC donors, four of them were heterozygous (inser-
tion/deletion) for and only one lacked (deletion/deletion)
the HLA-G 14 base pair, thus indicating a good capacity
to produce the soluble form of this important tolero-
genic molecule [27] in all cases.
Generation of mucosal T-cell lines
Fresh perendoscopic and surgical colonic mucosa speci-
mens were collected from both inflamed and non-
inflamed mucosa of patients with CD and from healthy
mucosa of control subjects. More precisely, non-
inflamed areas were considered those where a normal
vascular pattern and an intact mucosa were observed,
whereas inflamed areas were those where the normal
vascular pattern disappeared and various combinations
of the following lesions were evident: edema, erythema,
erosions, ulcers, pseudopolyps, granular and spontan-
eously bleeding zones, and nodular-cobblestone appear-
ance. In accordance with a previously described method
[28] that was slightly modified for this experimental set-
ting [29], the samples were immediately rinsed in salinesolution and placed in sterile medium: phosphate-
buffered saline (PBS) without calcium or magnesium,
supplemented with 100 U/ml penicillin, 100 mg/ml
streptomycin, and 5 % fetal calf serum. The epithelial
layer was then removed by adding 1 mM EDTA and
1 mM dithiothreitol (both from Sigma-Aldrich, St.
Louis, MO, USA). After continuous agitation for 1 h at
37 °C, the supernatant was removed and the remaining
tissue was digested by collagenase A from Clostridium
hystolyticum (1 mg/ml; Sigma-Aldrich) in 2 ml of
complete medium (Roswell Park Memorial Institute
(RPMI) 1640, 10 % fetal bovine serum, and the following
antibiotics: 1 % penicillin/streptomycin, 0.25 % gentami-
cin, and 0.4 % amphotericin B; all from Lonza Group
Ltd., Basel, Switzerland) and incubated for 2 h at 37 °C
and 5 % CO2 by stirring the plate every 15 min. The
crude cellular suspension was then passed through a 40-
μm filter cell strainer (BD Falcon™; Becton Dickinson,
Franklin Lakes, NJ, USA) and centrifuged for 10 min.
The cellular population obtained was composed of all
the white cells embedded in the mucosa after removal of
the epithelial layer, including monocyte macrophages, T
and B lymphocytes, natural killer cells, dendritic cells,
myofibroblasts, and granulocytes. After further centrifu-
gation, LPMCs were plated in 24-well flat-bottom tissue
culture plates (Sarstedt, Newton, NC, USA) at 0.5 × 106
cells per well density in the absence (ctr-TCLs) and pres-
ence of allogeneic MSCs (MSC-TCLs) at two different
MSC-to-T cell ratios (1:20 and 1:200) and in the pres-
ence of 1.5 × 106 autologous γ-irradiated PBMCs (35 Gy,
Raycell MK2; Best-Theratronics, Ottawa, ON, Canada)
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(Ficoll 1.077 g/ml; Amersham Biosciences, Little Chalfont,
UK), which were used as antigen-presenting cells, and
MDP (10 μg/ml; Sigma-Aldrich) in a final volume of
1.5 ml. The same MSC population was used from the be-
ginning to the end of each experiment, whereas different
MSC populations (from a minimum of three donors) were
applied in each experimental setting. After 24 h, 40 U/ml
IL-2 (R&D Systems, Minneapolis, MN, USA) was added,
and thereafter the cultures were fed twice weekly by re-
moving 50 % of the volume and replacing it with fresh
medium containing 40 U/ml IL-2. On the 10th day, a sec-
ond round of antigen + antigen-presenting cells + cytokine
stimulation was performed after washing the cellular sam-
ples in order to eliminate the residual cells that did not
grow in this condition which is specific for T cells. After a
further 10 days, TCLs were generated as assessed by flow
cytometric analysis (see the following paragraph), showing
an almost pure (i.e., >95 %) population of CD3+ T cells.
An aliquot of each TCL was then harvested from each ex-
perimental setting and used to evaluate the effects of
MSCs in terms of cell viability (as determined by trypan
blue dye exclusion), apoptotic rate, and immunophe-
notype (as assessed by flow cytometry) as well as prolif-
erative response upon re-stimulation with MDP, as
described more in depth in the specific paragraphs
below. Finally, supernatants from each ctr-TLC and
MSC-TCL at a 1:20 ratio were collected, filtered twice
by using 0.2-μm filters to exclude cells, and kept frozen
at −20 °C to be used for the analysis of the cytokine pro-
file, soluble HLA-G, and indoleamine 2,3-dioxygenase
(IDO) activity (see the specific paragraphs below). All of
the experimental conditions with both ctr-TCLs and
MSC-TCLs at a 1:20 ratio were also carried out in the
absence or presence of 100 μM of 1-methyl-DL-trypto-
phan (1-MT) (Sigma-Aldrich), a specific inhibitor of the
enzyme IDO, and by applying transwell membranes
(0.4-μm pore size; Costar; Corning Inc., Corning, NY,
USA) where MSCs were pre-plated in the lower com-
partment to produce an adherent monolayer 18 h before
the addition of the T cells in the upper compartment to
avoid cell-cell contact.
T-cell death and immunophenotype evaluation
The rate of T-cell death was evaluated by flow cytometry
(FACSCalibur; BD Biosciences, San Jose, CA, USA) with
CellQuest Software (Becton Dickinson, Milan, Italy) by
using APOPTEST™-FITC (Annexin V-FITC, Propidium
Iodide; Nexins Research, Kattendijke, The Netherlands),
in accordance with the instructions of the manufacturer,
to simultaneously analyse the rates of cells in the early
or late phase of apoptosis or dead cells. Furthermore,
the surface phenotype analysis was carried out by using
three-colour immunostaining (FITC, PerCD, and Cy)with fluorochrome-conjugated antibodies (anti-CD3,
-CD4, -CD8, -CD25, and -CD69) and the related iso-
type control antibodies (all by BD Biosciences Phar-
mingen, San Diego, CA, USA). The percentage of
positive cells was analysed with a gate set on viable
mononuclear cells based on their forward scatter/side
scatter characteristics.
Proliferative assay
In a 96-well round-bottom plate (Costar; Corning), cel-
lular aliquots from each established TCL were seeded at
a 5 × 104 per well concentration and cultured in the
presence of 1 × 105 autologous, γ-irradiated PBMCs
(35 Gy; Raycell MK2), and 10 μg/ml MDP as antigenic
stimulus or medium alone as negative control or the
polyclonal mitogen phytohemagglutinin (PHA 1 μg/ml;
Boehringer, Mannheim, Germany) as positive control.
Each experimental condition was carried out in tripli-
cate. The plates were then left in a humidified chamber
at 37 °C and 5 % CO2 for 48 h. Afterwards, T cells were
re-suspended and pulsed for 21 h with [3H]-thymidine
(0.5 μCi per well; GE Healthcare, Buc Cedex, France)
and harvested for the evaluation of [3H]-thymidine in-
corporation. The TCL proliferation rate was then
assessed in terms of stimulation index (SI) (i.e., the value
of counts per minute (cpm) with MDP/cpm with
medium alone). A positive response was defined as SI of
more than 2.
Cytokine profile
The levels of interferon-gamma (IFN-γ), tumor necrosis
factor-alpha (TNF-α), IL-6, IL-8, and IL-10 were measured
in cell-free supernatants by using the Custom Human 5-
Plex Array kit (SearchLight; Aushon Biosystems, Billerica,
MA, USA), whereas levels of IL-17A were measured with
the Human IL-17 Immunoassay (Quantikine ELISA; R&D
Systems), those of IL-21 with the Human IL-21 ELISA kit
(Cusabio Biotech Co., Ltd., Wuhan Hubei, China), and
those of transforming growth factor-beta 1 (TGF-β1)
with an ELISA kit (DRG Instruments GmbH, Marburg,
Germany) in accordance with the instructions of the
manufacturer. Optical density values were measured at
450 nm with a spectrophotometer (Bio-Rad Laboratories
Inc., Hercules, CA, USA), and the concentrations of cyto-
kines were calculated according to standard curves and
expressed as picograms per millilitre.
Detection of the soluble human leukocyte antigen-G
The soluble form of the HLA-G was measured by using
a standardized ELISA technique with a commercial kit
(Exbio/BioVendor, Praha, Czech Republic) in accordance
with the instructions of the manufacturer. Briefly, stan-
dards and samples were incubated in micro-titration wells
coated with a mouse monoclonal anti-HLA-G antibody.
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β2-microglobulin antibody labelled with horseradish
peroxidase was added to the wells and incubated with
the immobilized antibody-HLA-G complex. After further
washing, the remaining horseradish peroxidase-conjugated
antibody was allowed to react with the substrate (H2O2
with tetramethylbenzidine). The reaction was stopped by
the addition of acidic solution, and absorbance of the
resulting yellow product was measured with a spectropho-
tometer at 450 nm. The absorbance was proportional to
the concentration of HLA-G. A standard curve was drawn
by plotting absorbance values versus the HLA-G concen-
trations of standards, and the HLA-G levels in the samples
were determined by interpolation and expressed as nano-
grams per millilitre.
Indoleamine 2,3-dioxygenase activity
IDO activity was indirectly evaluated by quantifying
tryptophan and kynurenine concentrations in each TCL
supernatant by means of high-performance liquid chro-
matography by using the SCL-10 VP pump (Shimadzu,
Kyoto, Japan) as previously described [30]. L-tryptophan,
L-kynurenine, 3-nitro-L-tyrosine, trichloroacetic acid, po-
tassium phosphate, and acetonitrile for the elution buffer
(all from Sigma-Aldrich) were of analytical grade. Peak
area counts were used to calculate concentrations (EZStart
software, version 7.3, Shimadzu, Kyoto, Japan). Tryptophan
and kynurenine were referred to nitrotyrosine. The repro-
ducibility of the system was controlled by nitrotyrosine
counts, and only variations of less than 5 % were tolerated.
Small interfering RNA experiment
To knock down IDO, the ON-TARGETplus SMART-
pool small interfering RNA (siRNA) (L-010337-01-0005;
GE Dharmacon, Lafayette, CO, USA) was used. The se-






ACCCUUCAUACUU-3′; and sense, 5′-GAACGGGACA
CUUUGCUAAUU-3′, antisense, 5′-PUUAGCAAAGUG
UCCCGUUCUU-3′. The ON-TARGETplus siCONTROL
Nontargeting Pool (D-001810-10-05; GE Dharmacon) was
used as the negative control. siRNAs were transfected into
MSCs by the Amaxa Nucleofector II device (Lonza) and
the Human MSC Nucleofector kit (Lonza). Briefly, aliquots
of 5 × 105 MSCs were re-suspended in 100 μl of the
Nucleofector solution in the presence of 1.5 μg of IDO
or control siRNA and then electroporated by the U-23
program. Cells were immediately transferred into 37 °C
pre-warmed complete culture medium and plated onto
six-well dishes. After 72 h from transfection, cells wereharvested and lysed for the immunoblotting measure-
ment of IDO levels, while the supernatants were recov-
ered for the assessment of IDO activity and to be used
in functional assays.
Western blot analysis
Whole cell lysates were prepared in an ice-cold immuno-
precipitation buffer composed of 10 mM Tris base,
158 mM NaCl, 1 % Triton X-100, 1 % Na deoxycholate,
0.1 % SDS, and 1 Mm EGTA, with the addition of 2 %
Protease Inhibitor Cocktail (all by Sigma-Aldrich). The ly-
sates were then centrifuged at 4 °C (10 min, 13,000 revolu-
tions per minute), and the protein concentration of the
supernatants was determined by using the Bicinchoninic
Acid Kit for Protein Determination (Sigma-Aldrich) at
562 nm. The desired amount of protein (50 μg per lane)
was separated by 10 % SDS-PAGE gel (Invitrogen, part of
Life Technologies, Carlsbad, CA, USA) and transferred to
a 0.2-μm-pore nitrocellulose membrane (Bio-Rad Labora-
tories Inc.). After 1 h of blocking in 5 % skim milk powder
and TBS-T 1× (GE Healthcare and Sigma-Aldrich,
respectively), the membrane was incubated with a
mouse monoclonal anti-IDO antibody (1:4000; Abcam,
Cambridge, UK) overnight at 4 °C. After a 1-h incubation
at room temperature with the secondary polyclonal rabbit
anti-mouse antibody (1:1000; Dako, Glostrup, Denmark),
protein detection was performed by using developing liq-
uids (Kodak, Rochester, NY, USA) maintaining the nitro-
cellulose membrane in contact with the photographic
plate for 10 min. Finally, the blot was stripped and ana-
lysed for β-actin as an internal control by using a rabbit
anti-human polyclonal anti-β-actin antibody (1:5000;
Abcam). Films were acquired by using VersaDoc 3000
(Bio-Rad Laboratories Inc.), and the bands were measured
in terms of both surface area and intensity by the Quanti-
tyOne software (Bio-Rad Laboratories Inc.) and normal-
ized for β-actin values.
Time-lapse imaging
To follow the MSC-T cell dynamic interaction, the live
cell imaging technique was applied by using an Olympus
FluoView FV10i confocal microscope designed for live
cell registration (Olympus, Milan, Italy). For this purpose,
aliquots of TCLs generated from healthy, non-inflamed
CD and inflamed CD mucosa were seeded at 2.5 × 105
cells in 35/10 mm glass-bottom cell culture dishes (Greiner
Bio-One, Frickenhausen, Germany) where adherent
MSCs had been previously cultured until 80 % confluence.
Images of the three conditions used were recorded serially
every 30 min for 24 h.
Statistics
Continuous variables were described as median and
25th-75th percentiles or mean ± standard deviation,
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and percentages. A preliminary analysis of variance
(ANOVA) was used to determine the significance of all
the effects and interactions exerted by the tested param-
eters (cell viability, cell death, cell proliferation, cyto-
kines, and immunophenotype data). A Wilcoxon signed-
rank test (for comparisons between two groups) and a
Friedman test (for comparisons among three or more
groups) were then applied to the biological factors with
a statistically significant role at ANOVA in order to ob-
tain both further verification and specific inferencial data
from each direct comparison. A paired t test with Fish-
er’s exact test calculated the probability levels of groups
with more than four observations. Two-tailed tests were
used throughout, and values lower than 0.05 were con-
sidered statistically significant [31]. The analyses were
performed by using the Stat View 5.5 software package
for Macintosh (Abacus Concepts, Berkeley, CA, USA).
Results
Mesenchymal stem cell immunosuppressive effects
T-cell viability
Because a T-cell delayed apoptosis has been shown to
contribute significantly in sustaining chronic inflamma-
tion and tissue injury in CD [29, 32], we explored
whether MSCs are able to inhibit T-cell proliferation
while inducing cell death in this disease-specific setting.
As expected, the number of viable cells recovered from
both inflamed and non-inflamed CD mucosa was signifi-
cantly higher than that obtained when healthy mucosa
were used (Fig. 1, upper panel). However, when generat-
ing TCLs in the presence of MSCs, a statistically signifi-
cant reduction of viable cells was observed in those
cultures from both inflamed and non-inflamed CD mu-
cosa at 1:20 ratio in comparison with ctr-TCLs, thus ap-
proaching the values found in TCLs from healthy mucosa
(Fig. 1, upper panel). Moreover, when TCLs from inflamed
mucosa were used, this effect was also evident at the lower
ratio, although the number of viable cells was still higher
than that found when MSC-TCLs from healthy mucosa
were used. A specular pattern was found when analysing
the apoptotic rate (Fig. 1, central panel), with a lower rate
in ctr-TCLs from inflamed CD mucosa in comparison
with those from both non-inflamed CD and healthy mu-
cosa, whereas no difference was found when comparing
crt-TCLs from non-inflamed CD mucosa with those from
healthy mucosa. The incubation with MSCs at a 1:200 ra-
tio caused a slight increase of the apoptotic rate only on
TCLs from inflamed mucosa, and values approached
those of TCLs from non-inflamed CD mucosa. When the
1:20 ratio was used, the effect was more evident, and
MSC-TCLs from both inflamed and non-inflamed CD
mucosa displayed values approaching those found in
healthy mucosa. Furthermore, in regard to the proliferativeresponse to MDP re-stimulation (Fig. 1, lower panel), no
effect was observed on TCLs from healthy mucosa in any
condition applied, although they showed a robust response
to mitogen stimulus (data not shown). By contrast, when
TCLs from both inflamed and non-inflamed CD mucosa
were used, a significant proliferative response was clearly
evident in a basal condition, which was hampered by MSC
incubation at both 1:200 and 1:20 ratios.
T-cell immunophenotype
In regard to the immunophenotype (Fig. 2) of ctr-TCLs
isolated from inflamed mucosa of patients with CD, a
statistically significant upregulation of the activation
markers CD4+, CD8+, and CD4+CD25+ was found in
comparison with ctr-TCLs obtained from both non-
inflamed CD and healthy mucosa, whereas the CD69+
expression was found to be unchanged. When MSC-
TCLs were considered, a ratio-dependent decrease in
the frequency of CD4+ and CD4+CD25+ subsets, mir-
rored by a parallel increase of the CD8+ and CD69+ pop-
ulations with respect to ctr-TCLs, was clearly evident
when T cells from inflamed CD mucosa were used. A
similar, though lesser, effect was found when TCLs iso-
lated from non-inflamed CD mucosa were used, whereas
in MSC-TCLs harvested from healthy mucosa of control
subjects, only a ratio-dependent increase of CD8+ and
downregulation of the CD4+CD25+ subsets were found
when the 1:20 ratio in comparison with ctr-TCLs was
used. Remarkably, whereas almost all of the CD69+ cells
co-expressed the CD4+ surface marker in ctr-TCLs, a
considerable number of them co-expressed the CD8+
surface marker when MSC-TCLs from inflamed CD mu-
cosa were used (data not shown). Moreover, mainly in
this latter condition, a non-negligible number of CD4+
cells also expressed the CD8 molecule, as already found
in intestinal mucosa [33] and several autoimmune dis-
eases [34–36]; as a result, the sum of these two subsets
exceeded 100 %.
Cytokine profile
When the cytokine profile was analysed (Fig. 3), a statis-
tically significant upregulation of all of the molecules
analysed (i.e., TNF-α, IFN-γ, IL-6, IL-8, IL-10, IL-17A,
IL-21, and TGF-β1) was found in the supernatants of
ctr-TCLs isolated from inflamed CD mucosa in compari-
son with those obtained from healthy mucosa, whereas a
significant increase was observed only for the TNF-α,
IFN-γ, IL-8, IL-10, IL-17A, and IL-21 in the superna-
tants of ctr-TCLs isolated from non-inflamed CD mu-
cosa in comparison with those obtained from healthy
mucosa. In addition, an upregulation of TNF-α, IFN-γ,
IL-6, IL-8, IL-17A, and IL-21 was shown in ctr-TCLs
isolated from inflamed CD mucosa in comparison with
the levels found in ctr-TCLs isolated from non-inflamed
Fig. 1 (See legend on next page.)
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Fig. 1 Effects of mesenchymal stem cells on T-cell recovery. The histograms indicate the median values (range) of viable T cells (upper panel), their
dead rate (central panel, where the percentage of cell death represents both the Annexin+ and propidium iodide+ cells gated on lymphocyte
population), and proliferative response (lower panel) and refer to at least three separate experiments performed in triplicate in each experimental
condition. White panels indicate the use of T cells from healthy mucosa, the light grey panels indicate the use of T cells from non-inflamed
mucosa, and the dark grey panels indicate the use of T cells from inflamed mucosa of patients with Crohn’s disease. For comments, see the text.
At the preliminary analysis of variance, both the presence and absence of mesenchymal stem cells and the mucosa affected the variability of our
experimental parameters (P < 0.0001 in all cases). The reported P values derive from the non-parametric tests applied to the direct comparisons.
ctr-TCL control T-cell line, MSC-T T-cell lines obtained in the presence of mesenchymal stem cells
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ence of MSCs, a reduction in the levels of all of the pro-
inflammatory cytokines tested (TNF-α, IFN-γ, IL-17A,
and IL-21) was invariably found in the supernatants of
MSC-TCLs isolated from both inflamed and non-
inflamed mucosa of CD patients in comparison with ctr-
TCLs, whereas no modification was observed when
TCLs from healthy mucosa of control subjects were
used; the sole exception is IL-17A, which was almost
completely inhibited. Also, when the levels of these cyto-
kines between the supernatants of MSC-TCLs from both
inflamed and non-inflamed CD mucosa were compared
with those found in MSC-TCLs from healthy mucosa, a
strong upregulation is still present; the exception is the
IL-21 in non-inflamed mucosa. By contrast, an increase
in the pleiotropic cytokine IL-6 was found in the super-
natants of MSC-TCLs from both inflamed and non-
inflamed CD mucosa in comparison with ctr-TCLs,
whereas no modification was observed when TCLs were
obtained from control subjects. Surprisingly, the regula-
tory IL-10 production displayed the opposite pattern
since it was lowered by the incubation with MSCs when
T cells were isolated from both inflamed and non-
inflamed mucosa of CD patients, but it was upregulated
when T cells from control subjects were used, thus
highlighting the importance of the microenvironment
for MSC action. Finally, a significant increase in the
other main regulatory cytokine, TGF-β1, was evident
only in the supernatants of MSC-TCLs obtained from
inflamed CD mucosa in comparison with ctr-TCLs and
MSC-TCLs from both non-inflamed CD mucosa and
healthy mucosa. No significant modification of the levels
of IL-8 was found in MSC-TCLs in comparison with ctr-
TCLs in any of the experimental conditions, although
the levels were still upregulated in both inflamed and
non-inflamed CD mucosa in comparison with healthy
mucosa. Remarkably, when MSCs were cultured alone at
the same cellular density as that used in the MSC-to-T
cell 1:20 ratio (i.e., 250,000 cells per well), they produced
high levels of IL-6, IL-8, IL-10, and TGF-β but low levels
of IL-17 and IL-21 and undetectable levels of IFN-γ and
TNF-α. It is worth noting that the amount of IL-10 was
critically lowered when co-culturing MSCs with T cells,
thus suggesting that the microenvironment to whichMSCs are exposed plays a pivotal role in modulating
their secretory profile. This implies that the final con-
centration of each cytokine found in the MSC-to-T cell
co-culture supernatants does not simply represent the
sum of the amount produced by each cellular type, but
the final milieu resulting from their active interaction.
This is why the results were not normalized for the final
number of T cells (although the effect of MSCs on T-cell
growth might influence the cytokine levels), since an
equivalent amount of cells was plated at the set-up of
each condition. As far as the soluble HLA-G is con-
cerned, it was abundantly produced in MSC-TCLs co-
cultures from both inflamed (19.1 ± 1.9 and 91.3 ±
18.6 ng/ml at 1:200 and 1:20 ratio, respectively) and
non-inflamed (11.4 ± 3.7 and 72.2 ± 14.4 ng/ml at 1:200
and 1:20 ratio, respectively) CD mucosa in comparison
with MSC-TCLs from healthy mucosa (1.3 ± 0.9 and 3.5
± 1.6 ng/ml at 1:200 and 1:20 ratio, respectively; P < 0.05
for all), whereas undetectable amounts were evident in
ctr-TCL cultures. Furthermore, the levels of soluble
HLA-G produced by the five MSC populations used in
our experiments were very similar (median of 33.1 ng/
ml, range of 30.8–35.9).
Mesenchymal stem cell effects are mostly indoleamine
2,3-dioxygenase-dependent
In regard to the IDO activity, as indirectly measured by
kynurenine production [37], a statistically significant
increase in MSC-TCLs from both inflamed and non-
inflamed CD mucosa at either ratio applied was shown
in comparison with ctr-TCLs, whereas no effect was
observed when MSC-TCLs from healthy mucosa at a
1:200 ratio were used (Fig. 4a). As expected, the incu-
bation with the 1-MT caused a clear drop in the kynur-
enine levels in all of the experimental conditions tested
(P < 0.001 for all). By using siRNA targeting IDO, we
achieved a knockdown of more than 90 % of its expres-
sion in MSCs as measured by Western blot analysis
(Fig. 4b). Consequently, the kynurenine production fell
to levels of less than 1.0 μM with respect to the
amount secreted by non-treated MSCs (3.22 ± 0.1 μM)
or MSCs transfected with the non-targeting siRNA
control (3.87 ± 0.4 μM). We sought, therefore, to inves-
tigate whether the immunosuppressive effects of MSCs
Fig. 2 (See legend on next page.)
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Fig. 2 T-cell immunophenotype. The analysis of the expression of surface markers (CD3, CD4, CD8, CD25, and CD69) by T-cell lines generated in
the absence (ctr-TCLs) and in the presence of mesenchymal stem cells (MSCs) at two different MSC-to-T cell ratios is shown. All markers were
analysed in the gate of lymphocytes as delimited by side scatter-forward scatter parameters, but CD25 in that of CD4+ cells. The white panels
indicate the use of T cells from healthy mucosa, the light grey panels indicate the use of T cells from non-inflamed mucosa, and the dark grey
panels indicate the use of T cells from inflamed mucosa of patients with Crohn’s disease. For comments, see the text. Results are given as median
(midline), 25th-75th percentiles (box), and extremes (whiskers) of at least three different T-cell lines for each condition. P values are as in Fig. 1.
ctr-TCL control T-cell line, MSC-T T-cell lines obtained in the presence of mesenchymal stem cells
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MT or by using the supernatants of MSCs transfected
with siRNA targeting IDO.
Interestingly, when the 1-MT was added, an extraor-
dinary increase in the number of viable cells was ob-
served in both ctr-TCLs and MSC-TCLs from inflamed
mucosa and, to a lesser extent, even in TCLs from non-
inflamed CD mucosa; conversely, no changes were ob-
served in TCLs from healthy mucosa (Fig. 4c). Similarly,
the percentage of cell death appeared to be significantly
reduced in both ctr-TCLs and MSC-TCLs from CD mu-
cosa in comparison with TCLs from healthy mucosa in
both conditions, where no modification was observed
(Fig. 4d). Thus, the pro-apoptotic effect of MSCs on CD
TCLs (Fig. 1, central panel) was almost completely elimi-
nated. When the proliferative response to MDP re-
stimulation was considered, the addition of 1-MT had
no effect on TCLs from healthy mucosa and did not
modify the proliferation rate of MSC-TCLs from either
inflamed or non-inflamed CD mucosa in comparison
with ctr-TCLs (Fig. 4e), thus weakening the MSC action
(Fig. 1, lower panel). When the influence of the siRNA
targeting IDO on MSC effects was explored, a statisti-
cally significant increase of cell viability in co-cultures
using T cells from CD mucosa was invariably observed
in comparison with the co-cultures with T cells from
healthy mucosa (Fig. 4f ), along with a decrease in the
apoptotic rate (Fig. 4g) and restoration of the prolifera-
tive response to MDP (Fig. 4h). This did not occur when
the supernatants from MSCs transfected with the siRNA
non-targeting IDO were used. As far as the immunophe-
notype profile is concerned, the incubation with 1-MT
and the use of MSCs knockdown for IDO did not sub-
stantially modify the surface molecule expression of ei-
ther ctr-TCLs or MSC-TCLs in any of the experimental
conditions applied, except for the disappearance of the
CD69+ subset increase in MSC-TCLs from inflamed CD
mucosa (data not shown). Finally, when the IDO inhibi-
tor was added to the MSC-T cell co-cultures, substantial
changes, albeit to different extents, in the levels of all of
the cytokines tested were clearly observed (Table 2).
More specifically, a significant decrease in the TGF-β1,
IL-21, and IL-10 production and a strong inhibition of
IL-8 and IL-17A expression were observed in both ctr-
TCLs and MSC-TCLs isolated from inflamed and non-inflamed CD mucosa, whereas IL-6 appeared to be
inhibited in ctr-TCLs from both inflamed and non-
inflamed CD mucosa and in the MSC-TCLs from in-
flamed mucosa. Interestingly, a paradoxical pattern was
observed in regard to the IFN-γ levels, which appeared
to be reduced by the presence of 1-MT in ctr-TCLs but
upregulated in MSC-TCLs in all of the experimental
conditions. Also, the TNF-α was similarly decreased in
ctr-TCLs from CD mucosa but unchanged in MSC-
TCLs from both CD and healthy mucosa. Other than
the IFN-γ levels, the addition of 1-MT also substantially
reduced the levels of IL-8, IL-10, and IL-21 when using
both ctr-TCLs and MSC-TCLs generated from healthy
mucosa, where it decreased the levels of IL-6 and IL-
17A only in the supernatants of ctr-TCLs and those of
TGF-β1 only in MSC-TCLs. Finally, the addition of 1-MT
completely eliminated the HLA-G secretion in MSC-
TCLs co-cultures from both inflamed and non-inflamed
mucosa of patients with CD but did not modify the
amount produced by MSC-TCLs from healthy mucosa of
control subjects. Again, overlapping results were obtained
when the supernatants of MSCs transfected with siRNA
targeting IDO were used, in comparison with the use of
those of MSCs transfected with the siRNA non-targeting
IDO (data not shown).
Mesenchymal stem cell full action depends on cell-cell
contact
Since close proximity to T cells is needed for MSCs to
fulfil their immunological effect [7], we investigated the
relevance of cell-cell contact in enabling MSCs to dis-
play their action on CD mucosal T cells by using both
transwell and live cell imaging techniques. Specifically,
by applying a semipermeable membrane that does not
permit cell-cell contact, we found that even though the
effects of MSCs in terms of reduction of T-cell viability,
increase of cell death, and suppression of proliferative
response on TCLs from both inflamed and non-inflamed
CD mucosa still occurred in such conditions, they were
weaker than those observed when cells were permitted
to have direct contact, whereas no substantial modifica-
tion was found when TCLs from healthy mucosa were
used (Fig. 5). Similarly, the production of inflammatory
cytokines (TNF-α, IFN-γ, IL-17A, and IL-21) from TCLs
isolated from both inflamed and non-inflamed CD
Fig. 3 (See legend on next page.)
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Fig. 3 Cytokine profile. The cytokines TNF-α, IFN-γ, IL-6, IL-8, IL-10, IL-17A, IL-21, and TGF-β1 were measured by enzyme-linked immunosorbent
assay in cellular-free supernatants of T-cell lines generated in the absence or presence of mesenchymal stem cells (MSCs) at an MSC-to-T cell ratio
of 1:20 and of MSCs cultured alone. The measurements were performed in duplicate, and the results are given as median ± standard deviation.
The white panels indicate the use of T cells from healthy mucosa, the light grey panels indicate the use of T cells from non-inflamed mucosa, the
dark grey panels indicate the use of T cells from inflamed mucosa of patients with Crohn’s disease, and the black panels indicate the use of MSC
cultured alone. For comments, see the text. P values are as in Fig. 1. ctr-TCL control T-cell line, IFN-γ interferon-gamma, IL interleukin, MSC-T T-cell
lines obtained in the presence of mesenchymal stem cells, TGF-β1 transforming growth factor-beta 1, TNF-α tumor necrosis factor-alpha
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when the transwells were used, whereas that of IL-6,
TGF-β1, and especially HLA-G was reduced (ranging
from to 21 to 40 %), and the values of IL-8 remained un-
changed. Interestingly, the levels of IL-10 increased dra-
matically in the transwell experiments, thus indicating a
powerful interaction of T cells from CD mucosa with
MSCs upon cell-cell contact. In this regard, we explored
the dynamic of the contact between these two cell popula-
tions through the use of live time-lapse imaging, as shown
in more detail in the additional movie files (Additional
files 1, 2 and 3), where a more intensive interaction was
clearly evident when T cells isolated from inflamed mu-
cosa of CD patients were used compared with that
found when T cells from non-inflamed CD mucosa or
healthy mucosa were used. Moreover, we found that the
binding was not stable; in fact, continuous attachment
and detachment occurred during the first 6 h, after
which a growing number of floating apoptotic figures
became evident. Finally, no significant modification of
the cytokine levels when TCLs from healthy mucosa
were used and of the immunophenotype profile in any
experimental conditions was observed by applying the
transwells (data not shown).
Discussion
Following the evidence of efficacy of MSCs in treating
experimental colitis [38, 39], several clinical trials where
MSCs were applied as a new therapeutic strategy in
human CD have been carried out in the last few years
[14–20]. The results invariably highlighted the feasibil-
ity and safety of their systemic and local infusion in
both autologous [14, 17] and allogeneic [15, 16, 19, 20]
settings, while efficacy seemed to be optimal when lo-
cally injected into fistula tracks [17–19]. However, only
patients refractory to standard therapies had been re-
cruited, and, most importantly, no information on the
mechanisms by which MSCs exert their action on
pathogenic T cells has been available so far [13]. We,
therefore, carried out an ex vivo study aimed at evalu-
ating the modifications of mucosal TCLs in terms of
cell viability, immunophenotype, and cytokine profile
when cultured in the presence of MSCs and at explor-
ing whether they depend on the activity of IDO and
cell-cell contact.Mesenchymal stem cell immunosuppressive effects
Our results firstly demonstrated that MSCs are able to
normalize the T-cell viability in a dose-dependent man-
ner, mainly by increasing the apoptotic rate of TCLs
generated from inflamed mucosa. In this regard, a de-
layed T-cell apoptosis represents a pivotal mechanism in
sustaining chronic inflammation in CD [29, 32], and
MSCs had been previously proven capable of suppressing
activated T-cell functions by inducing a cell cycle arrest at
the G0-G1 phase [40, 41]. Our result of an inhibition of
the proliferative response upon antigen stimulation fits
with this evidence, and the neutral effect observed when
using TCLs from healthy mucosa supports the need for
an inflammatory environment to display their full im-
munomodulatory potential [7, 42]. In this regard, in-
deed, other than a numeric reduction of the T-cell
population isolated from CD mucosa, MSCs also caused
a shift of the immunophenotype toward a more tolero-
genic pattern and this was due to a significant decrease
in the activated CD4+CD25+ subset and an expansion of
the CD69+ one. CD69 is an immunoregulatory receptor
expressed by early-activated leukocytes at sites of chronic
inflammation and by lymphocytes at mucosal surface [43].
It has been demonstrated that a deficiency in CD69 leads
to increased production of pro-inflammatory cytokines
(such as TNF-α, IFN-γ, and IL-21), reduced FoxP3+ regu-
latory T-cell function, impaired oral tolerance, and more
severe colitis [44]. Furthermore, mice lacking CD69 de-
velop an exacerbated form of autoimmune disease, thus
indicating a pivotal regulatory role for CD69 in modulat-
ing T lymphocyte differentiation through the activation of
the Jak-3 signal transducer and activator of the transcrip-
tion (Stat)-5 signalling pathway, which inhibits T-helper
17 cell differentiation [45]. This evidence provides the
basis for the potential of MSCs in dampening inflamma-
tion in CD, where an upregulation of this pathway has
already been found [46]. Consistent with this notion is the
evidence of a statistically significant reduction of the levels
of all of the pro-inflammatory cytokines tested (namely
TNF-α, IFN-γ, IL-17A, and IL-21) in the supernatants of
MSC-TCLs from both inflamed and non-inflamed CD
mucosa, together with an upregulation of the immune-
regulatory TGF-β1 and the pleiotropic IL-6 molecules.
The ability of MSCs to secrete IL-6 upon stimulation with




Fig. 4 Indoleamine 2,3-dioxygenase (IDO) activity and effects. a The histograms indicate the median values (range) of kynurenine concentrations (the
white panels indicate the use of T cells from healthy mucosa, the light grey panels indicate the use of T cells from non-inflamed mucosa, and the dark grey
panels indicate the use of T cells from inflamed mucosa of patients with Crohn’s disease) of at least three separate experiments performed in triplicate in
each experimental condition. b Immunoblotting of mesenchymal stem cells (MSCs) transfected with both the siRNA targeting (MSC siRNA) or non-
targeting (MSC control) IDO with the mouse monoclonal anti-IDO antibody. The protein levels were measured by scanning densitometry as band area
and band intensity, expressed as arbitrary units, and normalized toward β-actin levels. In the upper part of the panel, a representative case is shown, and
in the lower part, the values are given. c-h The histograms indicate the median values (range) of viable T cells, their dead rate, and proliferative response
in the presence of 1-MT (c-e) and transfected MSC (f-h) and refer to at least three separate experiments performed in triplicate in each experimental
condition. White panels indicate the use of T cells from healthy mucosa, the light grey panels indicate the use of T cells from non-inflamed mucosa, and
the dark grey panels indicate the use of T cells from inflamed mucosa of patients with Crohn’s disease. For comments, see the text. At the preliminary
analysis of variance, both the 1-MT and the use of MSC transfected with siRNA targeting IDO affected the variability of our experimental parameters
(P< 0.0001 in all cases). The reported P values derive from the non-parametric tests applied to the direct comparisons. ctr-TCL control T-cell line, MSC-T
T-cell lines obtained in the presence of mesenchymal stem cell, 1-MT 1-methyl-DL-tryptophan, SI stimulation index, siIDO siRNA small interfering RNA
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Table 2 Cytokine and HLA-G levels on cell-free supernatants with 1MT
Condition TNF-α IFN-γ IL-6 IL-8 IL-10 IL-17A IL-21 TGF-β1 HLA-G
(pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (ng/ml)
Healthy mucosa ctr-TCLs 55.3 ± 20.1 478.9 ± 100.7 409.8 ± 100.3 2005.4 ± 380.7 9.8 ± 2.8 18.9 ± 4.5 45.9 ± 9.5 555.9 ± 74.4 0.2 ± 0.07
n.s. p < 0.05 p < 0.05 p < 0.01 p < 0.01 p < 0.001 p < 0.05 n.s. n.s.
MSC:T 1:20 70.3 ± 17.9 998.4 ± 209.4 4690.5 ± 220.4 2499.7 ± 277.6 20.8 ± 5.7 18.6 ± 3.5 38.6 ± 9.8 499.2 ± 29.1 1.2 ± 0.4
n.s. p < 0.01 n.s. p < 0.01 p < 0.01 n.s. p < 0.05 p < 0.05 n.s.
Non inflamed
Crohn’s mucosa
ctr-TCLs 290.50 ± 108.4 654.65 ± 88.1 725.73 ± 117.9 2387.0 ± 328.4 11.5 ± 1.8 23.2 ± 2.9 57.5 ± 8.0 517.1 ± 26.9 1.2 ± 0.1
p < 0.05 p < 0.01 p < 0.05 p < 0.001 p < 0.001 p < 0.001 p < 0.01 p < 0.05 n.s.
MSC:T 1:20 402.3 ± 109.7 1117.8 ± 156.5 5154.68 ± 855.2 2408.1 ± 389.7 23.8 ± 3.8 23.6 ± 2.7 45.2 ± 4.7 567.4 ± 128.1 1.4 ± 0.3
n.s. p < 0.05 n.s. p < 0.001 p < 0.01 p < 0.05 p < 0.01 p < 0.05 p < 0.01
Inflamed Crohn’s
mucosa
ctr-TCLs 428.2 ± 175.8 998.4 ± 328.4 3331.1 ± 538.2 2623.3 ± 475.8 14.1 ± 3.3 36.5 ± 4.2 128.9 ± 9.3 853.2 ± 97.0 1.1 ± 0.3
p < 0.01 p < 0.01 p < 0.01 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.05 n.s.
MSC:T 1:20 827.4 ± 202.1 1290.3 ± 290.5 5468.4 ± 990.3 2318.9 ± 392.1 33.4 ± 7.3 13.2 ± 2.9 127.9 ± 8.3 1071.1 ± 197.7 1.3 ± 0.1
n.s. p < 0.05 p < 0.01 p < 0.001 p < 0.01 p < 0.01 p < 0.05 p < 0.05 p < 0.01
Data are expressed as mean ± standard deviation. The P values shown refer to the differences between the levels of each molecule on the supernatants of both the ctr-TCLs and MSC-TCLs at MSC-T cell 1:20 ratio in
presence of 1-MT with those found in the cultures performed in the absence of 1-MT














Fig. 5 Effects of cell-cell contact on T-cell recovery. The histograms indicate the median values (range) of viable T cells (left panel), their dead rate
(central panel, where the percentage of cell death represents both the Annexin+ and propidium iodide+ cells gated on lymphocyte population),
and proliferative response (right panel) and refer to at least three separate experiments performed in triplicate in each experimental condition.
White panels indicate the use of T cells from healthy mucosa, the light grey panels indicate the use of T cells from non-inflamed mucosa, and the
dark grey panels indicate the use of T cells from inflamed mucosa of patients with Crohn’s disease. For comments, see the text. At the preliminary
analysis of variance, the use of the transwells affected the variability of our experimental parameters (P < 0.0001 in all cases). The reported P values
derive from the non-parametric tests applied to the direct comparisons. TW transwell
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ition of T-cell response upon antigen stimulation since IL-
6 production has been shown to suppress activated T-cell
proliferation [47]. Moreover, the levels of two cytokines
found abundantly secreted by unstimulated MSCs (i.e., IL-
8 and IL-10) appeared unaffected or critically reduced in
MSC-TCLs, respectively. In this regard, one would expect
a higher concentration of IL-10 in MSC-T cell co-cultures,
as found in different experimental conditions where this
cytokine proved to be responsible for the immunomodula-
tory effects of MSCs [48]. However, contrasting results
were obtained when measuring the IL-10 levels in culture
supernatants of T cells isolated from mice with collagen-
induced arthritis re-stimulated with collagen II in vitro
since they were found to be either reduced [49] or in-
creased [50], depending on whether the T cells were iso-
lated from mice treated with MSCs or left untreated,
respectively. As far as CD is concerned, the relevance of
the IL-10 pathway in dampening inflammation was sub-
stantiated by the development of severe colitis in infants
with mutations of IL-10, IL-10RA, or IL-10RB genes [51]
and in mice deficient in IL-10 that underwent spontan-
eous development of colitis [52]. Unfortunately, the use of
human recombinant IL-10 as a new immunomodulatory
therapy has been largely disappointing [53] because it in-
duced clinical response in only a small proportion of pa-
tients (23.5 %) when used at medium doses (5 μg/kg)
while worsening the disease at higher doses (8 μg/kg) be-
cause of induction of IFN-γ secretion [54]. Once again, it
is likely that peculiar in vivo and in vitro microenviron-
ments differently influence the effect of targeted therapies,
while MSCs, though found to lower the levels of IL-10in vitro, appeared to display a more complex mechanism
of action which may be of benefit in blocking the disease-
specific pathogenic effector arm and restoring immune
tolerance. Our results, indeed, cannot exclude that in the
target tissue, IL-10 may contribute to the attenuation of
the autoimmune response by MSCs, mainly through in-
duction of regulatory T cells and associated cytokines
(i.e., IL-10 and TGF-β).
Mesenchymal stem cell effects are mostly indoleamine
2,3-dioxygenase-dependent
This enzyme is considered the main actor in inhibiting
T-cell growth and function through the degradation of
tryptophan, an amino acid essential for lymphocyte pro-
liferation whose depletion induces apoptosis, and the
formation of toxic metabolites, such as kynurenine [37].
As far as MSCs are concerned, the IFN-γ gradient pro-
duced by locally activated T cells [55, 56] addresses
MSCs toward areas of inflammation and induces the ex-
pression of IDO [57]. Our findings fully support this evi-
dence because high levels of kynurenine were found in
those MSC-TCL co-cultures from CD mucosa that dis-
appeared following the addition of the specific IDO in-
hibitor, the 1-MT, whereas low levels were observed in
co-cultures from healthy mucosa. Furthermore, the pres-
ence of discrete amounts of kinurenine also in ctr-TCLs
might be explained by the ability of certain immune cell
populations to display IDO activity [58], including den-
dritic cells [59] and regulatory T cells [60]. Nevertheless,
our evidence of a full suppression of kynurenine release
in MSC-T cell co-cultures through the use of both 1-MT
and siRNA knockdown IDO supports the attribution of
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following the block of either IDO activity or expression,
the effects of MSCs on T-cell viability, apoptotic rate,
and proliferative response were almost completely
reverted when T cells isolated from inflamed CD mucosa
were used. In addition, the secretion of most cytokines
was significantly reduced, thus indicating that this en-
zyme contributes greatly to controlling their production,
either directly by affecting the number of viable T cells
or indirectly by suppressing the production of the mas-
ter switch molecule for immune tolerance, the soluble
HLA-G [61, 62]. This result was partially at variance
with the evidence of an upregulation of both surface ex-
pression and shedding of HLA-G in dendritic cells when
stimulated with both tryptophan and its by-product
kinurenine [63]. It is conceivable, therefore, that these
two molecules might exert opposite influences on the
production of HLA-G by MSCs, with kinurenine acting
as a stimulator and tryptophan operating a sort of nega-
tive feedback. Taken together, our findings clearly sup-
port the notion that IDO activity plays a prominent role
in triggering MSC immunological action in this patho-
logical condition.
Mesenchymal stem cell full action depends on cell-cell
contact
It has been found that a cognate interaction between MSCs
and allo-stimulated T cells is needed to obtain full HLA-G
secretion [62] and immunological function [64, 65];
therefore, we investigated whether cell-cell contact is
necessary in order for MSCs to display their effects in
our disease-specific setting, by using both transwell and
live cell imaging techniques. Our finding of the estab-
lishment of more intensive MSC-T cell interaction
when T cells isolated from inflamed CD mucosa were
used, compared with that observed with T cells from non-
inflamed CD mucosa or healthy mucosa, supports this no-
tion. Moreover, at variance with previous evidence show-
ing that activated T lymphocytes bind to MSCs during the
first 4 h of culture and then remain trapped for up to 60 h
[66], we found that the binding was not stable. In fact,
continuous attachment and detachment occurred during
the first 6 h, after which a growing number of apoptotic
figures became evident (Supplemental files). A possible
explanation of this phenomenon is the upregulation of ad-
hesion molecules [67, 68] and chemokines and their re-
ceptors [69] on MSC surface following inflammatory
stimuli, which enable them to bind to T lymphocytes with
high affinity and in a dynamic manner. It is conceivable,
therefore, that this mutual interaction enhances IDO ac-
tivity which, in turn, induces T-cell apoptosis. The in-
volvement of contact-dependent mechanisms was also
demonstrated by the use of transwell cultures, which
separate MSCs from the responder lymphocytes by asemipermeable membrane. In this condition, although
the immunosuppressive impact of MSCs still occurred
through the reduction of both T-cell viability and pro-
duction of inflammatory cytokines, it was much weaker
than when cells were allowed to have direct contact.
This finding fits with the evidence that both cell-cell
contact and secreted molecules are necessary for a
stronger suppressive effect of MSCs on T cells [70]. Fi-
nally, the fact that, in co-cultures of MSCs and T cells
from inflamed CD mucosa where cell contact was not
permitted, the levels of TGF-β and IL-10 underwent sig-
nificant modification compared with those in cell con-
tact conditions underlines the need for close interaction
between MSCs and T cells in order to license MSCs to
exhibit their full potential in orchestrating the immuno-
logical response. In this regard, it has recently been sug-
gested that the expression of both the immune-regulatory
molecules TGF-β and HLA-G is modulated in a contact-
dependent mechanism [62, 71].Conclusions
The results of the present study provide new insights
into the immunological mechanisms by which MSCs
may dampen the exaggerated inflammatory response of
mucosal T cells in CD through the upregulation of IDO
activity and HLA-G production. Moreover, to exert
their full immunosuppressive potential, MSCs first
need to be activated by inflammatory signals and to es-
tablish close cell-cell contact with target cells. Our evi-
dence of close, dynamic interaction between MSCs and
T cells from CD mucosa suggests that T cells serve as
critical feedback signal factors in promoting the immu-
nodulatory action of MSCs and supports the hypothesis
that MSCs should be able to deliver their effects to the
exact sites of active inflammation. These findings, to-
gether with the multipotency, low immunogenicity,
amenability to ex vivo expansion, and genetic stability,
pave the way for a therapeutic use of MSCs in this
pathological condition and not only in refractory cases.
Additional files
Additional file 1: Mesenchymal stem cells with T cells from
inflamed Crohn’s mucosa. Representative time-lapse imaging of a
co-culture with bone marrow-derived mesenchymal stem cells of a
healthy donor and T cells isolated from inflamed mucosa of a patient
with Crohn’s disease. A dynamic and intense interaction is clearly evident
mostly during the first 6 h, when the binding between these two cell
populations is non-fixed but instead appears as a continuous attachment
and detachment, after which a growing number of cells with morphological
features of apoptosis (those with nuclear fragmentation and cellular
swelling) and apoptotic bodies become evident. The images were serially
recorded every 30 min for 12 h. Magnification: 100×. (ZIP 6780 kb)
Additional file 2: Mesenchymal stem cells with T cells from
non-inflamed Crohn’s mucosa. Representative time-lapse imaging of a
co-culture with bone marrow-derived mesenchymal stem cells of a
Ciccocioppo et al. Stem Cell Research & Therapy  (2015) 6:137 Page 17 of 19healthy donor and T cells isolated from non-inflamed mucosa of a patient
with Crohn’s disease. A slow and continuous interaction is evident, and a
few cells with morphological features of apoptosis (those with nuclear
fragmentation and cellular swelling) and apoptotic bodies become
evident at the end of the period of registration. The images were serially
recorded every 30 min for 12 h. Magnification: 100×. (ZIP 6800 kb)
Additional file 3: Mesenchymal stem cells with T cells from healthy
mucosa. Representative time-lapse imaging of a co-culture with bone
marrow-derived mesenchymal stem cells of a healthy donor and T cells
isolated from healthy mucosa of a control subject. The absence of any
active interaction during the entire period of registration is clearly evident.
The images were serially recorded every 30 min for 12 h. Magnification:
100×. (ZIP 9020 kb)
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